Home > News > First Clinical Validation Study on Nano-JETA Platform
May 6th, 2005
First Clinical Validation Study on Nano-JETA Platform
Abstract:
Acrongenomics Inc. a Research and Development company focusing in the field of nanobiotechnology has managed to reshape key IVD molecular applications such as PCR, ELISA and Real Time PCR through its Nano-JETA(TM) technology platform, by integrating nanotechnology into molecular biology.
Source:
businesswire
Related Links |
Related News Press |
Nanomedicine
New micromaterial releases nanoparticles that selectively destroy cancer cells April 5th, 2024
Good as gold - improving infectious disease testing with gold nanoparticles April 5th, 2024
Researchers develop artificial building blocks of life March 8th, 2024
Announcements
NRL charters Navy’s quantum inertial navigation path to reduce drift April 5th, 2024
Discovery points path to flash-like memory for storing qubits: Rice find could hasten development of nonvolatile quantum memory April 5th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||